NCT05061563View on ClinicalTrials.gov

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

February 23, 2022

Conditions

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and MenHot Flashes

Interventions

DRUG

Elinzanetant (BAY3427080)

Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.

DRUG

Esomeprazole

Esomeprazole given orally once daily for 5 days in Period 2.

Trial Locations (1)

9728 NZ

PRAHealthSciences, Groningen